Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.

[1]  M. Kutryk,et al.  Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. , 2015, Circulation research.

[2]  V. Fuster,et al.  Combination Proximal Pulmonary Artery Coiling and Distal Embolization Induces Chronic Elevations in Pulmonary Artery Pressure in Swine , 2015, PloS one.

[3]  D. Sigg,et al.  Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  V. Fuster,et al.  Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. , 2014, American journal of physiology. Heart and circulatory physiology.

[5]  H. Palevsky,et al.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. , 2014, Chest.

[6]  V. Fuster,et al.  Swine Model of Chronic Postcapillary Pulmonary Hypertension with Right Ventricular Remodeling: Long-Term Characterization by Cardiac Catheterization, Magnetic Resonance, and Pathology , 2014, Journal of Cardiovascular Translational Research.

[7]  L. G. Johnson,et al.  Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. , 2014, Human gene therapy.

[8]  K. Zsebo,et al.  Long-Term Effects of AAV1/SERCA2a Gene Transfer in Patients With Severe Heart Failure: Analysis of Recurrent Cardiovascular Events and Mortality , 2014, Circulation research.

[9]  J. Lumens,et al.  Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. , 2013, Journal of the American College of Cardiology.

[10]  F. Martinez,et al.  Pulmonary hypertension due to left heart diseases. , 2013, Journal of the American College of Cardiology.

[11]  E. Michelakis,et al.  Pulmonary Arterial Hypertension: Challenges in Translational Research and a Vision for Change , 2013, Science Translational Medicine.

[12]  A. Schambach,et al.  Gene therapy on the move , 2013, EMBO molecular medicine.

[13]  M. Humbert,et al.  Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension , 2013, Circulation.

[14]  R. Hajjar,et al.  Percutaneous Approaches for Efficient Cardiac Gene Delivery , 2013, Journal of Cardiovascular Translational Research.

[15]  Yuhui Zhang,et al.  Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. , 2013, Chest.

[16]  T. Weber,et al.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. , 2013, Human gene therapy methods.

[17]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.

[18]  R. Hajjar.  Potential of gene therapy as a treatment for heart failure. , 2013, The Journal of clinical investigation.

[19]  Simon Stewart,et al.  Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort , 2012, Heart.

[20]  Karine Tremblay,et al.  Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial , 2012, Gene Therapy.

[21]  J. Yuan,et al.  New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. , 2012, American journal of physiology. Heart and circulatory physiology.

[22]  K. Zsebo,et al.  Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[24]  Barry Greenberg,et al.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.

[25]  P. Reynolds,et al.  Targeted gene delivery of BMPR2 attenuates pulmonary hypertension , 2011, European Respiratory Journal.

[26]  P. Reynolds.  Gene therapy for pulmonary hypertension: prospects and challenges , 2011, Expert opinion on biological therapy.

[27]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[28]  R. Hajjar,et al.  SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. , 2010, Molecular Therapy.

[29]  Kurt R Stenmark,et al.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[30]  D. Mancini,et al.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. , 2009, Journal of cardiac failure.

[31]  R. Hajjar,et al.  The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases , 2008, Nature Clinical Practice Cardiovascular Medicine.

[32]  U. Ikeda,et al.  Adenoassociated Virus–Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats , 2007, Hypertension.

[33]  S. Archer,et al.  Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[34]  F. López-Ríos,et al.  Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure , 2005, European journal of heart failure.

[35]  S. Archer,et al.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.

[36]  J. Clancy,et al.  Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. , 2004, Chest.

[37]  J. Dyck,et al.  In Vivo Gene Transfer of the O2-Sensitive Potassium Channel Kv1.5 Reduces Pulmonary Hypertension and Restores Hypoxic Pulmonary Vasoconstriction in Chronically Hypoxic Rats , 2003, Circulation.

[38]  T. Flotte,et al.  Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  T. Giles,et al.  Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Collen,et al.  Aerosol Gene Transfer With Inducible Nitric Oxide Synthase Reduces Hypoxic Pulmonary Hypertension and Pulmonary Vascular Remodeling in Rats , 2000, Circulation.

[41]  S. Eddahibi,et al.  Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. , 2000, American journal of respiratory cell and molecular biology.

[42]  T. Ogihara,et al.  Gene Transfer of Human Prostacyclin Synthase Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats , 2000, Circulation.

[43]  L. Ortiz,et al.  Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. , 1999, Circulation research.

[44]  K. Rapti,et al.  Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  T. Bivalacqua,et al.  Chronic Hypoxia-induced Pulmonary Hypertension in the Mouse Related Peptide to the Lung Attenuates − in Vivo Gene Transfer of Prepro-calcitonin Gene in Vivo Gene Transfer of Prepro-calcitonin Gene–related Peptide to the Lung Attenuates Chronic Hypoxia-induced Pulmonary Hypertension in the Mouse , 2022 .